Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Defining NASH from a multi-omics systems biology perspective

    Research output: Contribution to journalReviewResearchpeer-review

  2. Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. ECCO topical review: Refractory Inflammatory Bowel Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The burden of inflammatory bowel disease in Europe in 2020

    Research output: Contribution to journalReviewResearchpeer-review

  • Ahmad Albshesh
  • Joshua Taylor
  • Edoardo V Savarino
  • Marie Truyens
  • Alessandro Armuzzi
  • Davide G Ribaldone
  • Ariella Bar-Gil Shitrit
  • Morine Fibelman
  • Pauliina Molander
  • Claire Liefferinckx
  • Stephane Nancey
  • Mohamed Korani
  • Mariann Rutka
  • Manuel Barreiro-de Acosta
  • Viktor Domislovic
  • Gerard Suris
  • Carl Eriksson
  • Catarina Alves
  • Afroditi Mpitouli
  • Caroline di Jiang
  • Katja Tepeš
  • Marina Coletta
  • Kalliopi Foteinogiannopoulou
  • Javier P Gisbert
  • Hadar Amir-Barak
  • Mohamed Attauabi
  • Jakob Seidelin
  • Waqqas Afif
  • Carla Marinelli
  • Triana Lobaton
  • Daniela Pugliese
  • Nitsan Maharshak
  • Anneline Cremer
  • Jimmy K Limdi
  • Tamás Molnár
  • Borja Otero-Alvarin
  • Zeljko Krznaric
  • Fernando Magro
  • Konstantinos Karmiris
  • Tim Raine
  • David Drobne
  • Ioannis Koutroubakis
  • Maria Chaparro
  • Henit Yanai
  • Johan Burisch
  • Uri Kopylov
View graph of relations

BACKGROUND: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described.

AIMS AND METHODS: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD.

RESULTS: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5).

CONCLUSION: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

Original languageEnglish
Article number2914
JournalJournal of Clinical Medicine
Volume10
Issue number13
ISSN2077-0383
DOIs
Publication statusPublished - Jul 2021

    Research areas

  • Crohn's disease, anti-TNF failure, treatment failure, treatment response, ustekinumab, vedolizumab, Anti-TNF failure, Ustekinumab, Treatment failure, Treatment response, Vedolizumab, Crohn’s disease

ID: 66573797